Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment

Objectives: We aimed to assess safety, tolerability, and Plasmodium vivax relapse rates of ultra-short course (3.5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment. Methods: Childre...

Popoln opis

Bibliografske podrobnosti
Main Authors: Sze-Ann Woon, Brioni R. Moore, Moses Laman, Paula Tesine, Lina Lorry, Bernadine Kasian, Phantica Yambo, Gumul Yadi, William Pomat, Kevin T. Batty, Sam Salman, Leanne J. Robinson, Timothy M.E. Davis, Laurens Manning
Format: Article
Jezik:English
Izdano: Elsevier 2023-05-01
Serija:International Journal of Infectious Diseases
Teme:
Online dostop:http://www.sciencedirect.com/science/article/pii/S1201971223000863